The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo‐resistant bladder cancer-Reference-Cited by-同舟云学术

The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo‐resistant bladder cancer

Published:2024-03-11 Issue:6 Volume:44 Page:700-704
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Tong Zhichao¹²³⁴^ORCID,Zhao Yubo¹²,Bai Shiyu²⁴,Ebner Benedikt³⁵,Lienhard Lou³,Zhao Yuling³,Wang Ziqi¹²,Pan Qi³⁶,Guo Pengyu¹²,Bracht Thilo⁷⁸^ORCID,Sitek Barbara⁷⁸,Gschwend Jürgen E.³,Xu Wanhai¹²^ORCID,Nawroth Roman³

Affiliation:

1. Department of Urology Harbin Medical University Cancer Hospital Harbin Heilongjiang P. R. China

2. NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics Harbin Medical University Harbin Heilongjiang P. R. China

3. Department of Urology Klinikum rechts der Isar, Technical university of Munich Munich Germany

4. Department of Urology The Fourth Hospital of Harbin Medical University Harbin Heilongjiang P. R. China

5. Department of Urology Ludwig‐Maximilians‐University of Munich Munich Germany

6. Department of Urology Shanghai General Hospital, Shanghai Jiao Tong University Shanghai P. R. China

7. Medizinisches Proteom‐Center, Ruhr‐Universität Bochum Bochum Germany

8. Clinic for Anesthesiology, Intensive Care and Pain Therapy, University Medical Center Knappschaftskrankenhaus Bochum Bochum Germany

Funder

China Postdoctoral Science Foundation

Postdoctoral Scientific Research Development Fund of Heilongjiang Province

National Key Research and Development Program of China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12532

Reference10 articles.

1. Bladder Cancer

2. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

3. Targeting CDK4 and CDK6 in cancer

4. CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status

5. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy